Amtagvi was Iovance Biotherapeutics’s largest product and service line in fiscal 2025, bringing in $220.02M of $263.50M (83%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Amtagvi | — | $103.57M | $220.02M |
| Proleukin | $1.19M | $60.50M | $43.48M |
| Total | $1.19M | $164.07M | $263.50M |
Iovance Biotherapeutics brought in $263.50M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 60.6% from $164.07M in fiscal 2024. Amtagvi was the largest at $220.02M (83.5%), ahead of Proleukin at $43.48M (16.5%).
Compared with fiscal 2024, Amtagvi grew 112.4% to $220.02M, while Proleukin fell 28.1% to $43.48M.
Iovance Biotherapeutics began breaking out Amtagvi in fiscal 2024, when it brought in $103.57M.
Federal Income Tax was Iovance Biotherapeutics’s largest region in fiscal 2025, bringing in $259.01M of $263.50M (98%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Federal Income Tax | — | $161.04M | $259.01M |
| Non-Us | $1.19M | $3.03M | $4.49M |
| Total | $1.19M | $164.07M | $263.50M |
Iovance Biotherapeutics brought in $263.50M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 60.6% from $164.07M in fiscal 2024. Federal Income Tax was the largest at $259.01M (98.3%), ahead of Non-Us at $4.49M (1.7%).
Iovance Biotherapeutics began breaking out Federal Income Tax in fiscal 2024, when it brought in $161.04M.
Iovance Biotherapeutics (IOVA) reports its revenue by product and service and by geography. In fiscal 2025, Amtagvi was its largest product and service line, bringing in $220.02M (83.5% of the total), followed by Proleukin at $43.48M (16.5%).
Amtagvi was Iovance Biotherapeutics' largest product and service line in fiscal 2025, bringing in $220.02M, or 83.5% of the $263.50M total across its two product and service lines.
Federal Income Tax was Iovance Biotherapeutics' largest region in fiscal 2025, bringing in $259.01M, or 98.3% of the $263.50M total across its two regions.
Amtagvi grew faster than Proleukin in fiscal 2025, up 112.4% from $103.57M to $220.02M. Proleukin fell 28.1% to $43.48M.
Every figure comes from Iovance Biotherapeutics' annual financial filings, as reported. Each line keeps the name Iovance Biotherapeutics gives it, and years follow its fiscal calendar.
Iovance Biotherapeutics' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.